The HLA-DQ2 and HLA-DQ8 test looks for immune-system gene combinations that make celiac disease possible. It is most useful for ruling celiac disease out when the diagnosis is uncertain, especially after someone has already stopped eating gluten or when antibody tests and intestinal biopsy findings do not agree. A negative result for the main celiac-associated HLA patterns makes celiac disease very unlikely. A positive result is different: it shows genetic susceptibility, not active disease, because many healthy people carry DQ2 or DQ8 and never develop celiac disease. The test uses blood, saliva, or a cheek swab and does not require fasting or gluten exposure. Results may list DQ2.5, DQ2.2, DQ8, DQA1 and DQB1 alleles, or a risk category. Correct interpretation depends on the exact alleles, family history, symptoms, celiac antibody testing, total IgA, and sometimes an upper endoscopy with small-intestinal biopsies.
- A negative DQ2/DQ8 result makes celiac disease very unlikely, though laboratories may also assess rarer DQ2.2 or DQ7.5 patterns.
- A positive result means susceptibility only; it does not prove gluten is causing symptoms or intestinal damage.
- The test remains accurate after starting a gluten-free diet because HLA genes do not change with diet.
- No fasting, medication pause, or gluten challenge is needed for the genetic test itself.
- DQ2.5 with two copies of DQB1*02 generally carries more celiac risk than one copy, DQ8, or partial DQ2 patterns.
Table of Contents
- What the HLA-DQ2 and HLA-DQ8 test measures
- When the test is most useful
- Sample, preparation, and test methods
- How to understand positive and negative results
- How genetics fits with antibodies and biopsy
- Family testing and testing in children
- Limitations and common interpretation errors
- Next steps after the result
What the HLA-DQ2 and HLA-DQ8 test measures
HLA stands for human leukocyte antigen. HLA proteins sit on the surface of immune cells and help present small protein fragments to T cells. The DQ proteins are built from two parts: an alpha chain encoded mainly by HLA-DQA1 and a beta chain encoded mainly by HLA-DQB1. Particular alpha-beta combinations can bind gluten-derived peptides in a way that supports the immune reaction seen in celiac disease.
The two best-known combinations are HLA-DQ2 and HLA-DQ8, but a detailed report may use more precise names.
| Reported pattern | Common allele combination | General interpretation |
|---|---|---|
| DQ2.5 | DQA1*05 with DQB1*02 | Strongest and most common celiac-associated HLA pattern |
| DQ8 | DQA1*03 with DQB1*03:02 | Established susceptibility pattern, generally lower risk than DQ2.5 |
| DQ2.2 | DQA1*02 with DQB1*02:02 | Lower-risk celiac-associated pattern |
| DQ7.5 | DQA1*05 with DQB1*03:01 | Uncommon susceptibility pattern, often considered when DQ2.5 and DQ8 are absent |
| No celiac-associated combination | None of the relevant paired alleles detected | Celiac disease becomes very unlikely |
“DQ2 positive” often means DQ2.5, but laboratories differ. Some report only DQ2 and DQ8 as present or absent. Others list every DQA1 and DQB1 allele, identify whether the alleles sit on the same chromosome or opposite chromosomes, and estimate a relative risk category. The fuller report can distinguish a complete DQ2.5 molecule from a single “half-DQ2” component.
Most people with confirmed celiac disease carry DQ2.5. A smaller group carries DQ8, and a minority carries other celiac-compatible DQ combinations. These genes are necessary susceptibility factors in almost all cases, but they are not sufficient by themselves. Gluten exposure, additional genes, immune regulation, and other influences determine who develops disease.
A DQ2/DQ8 test is a targeted form of genetic screening for disease susceptibility. It does not examine the entire genome, diagnose food allergy, measure gluten exposure, or show current intestinal injury.
When the test is most useful
HLA testing is not usually the first test for a person who is eating gluten and can have standard celiac blood work. Tissue transglutaminase IgA, total IgA, and other selected antibody tests provide more direct evidence of an active immune response. HLA testing becomes especially valuable when the ordinary pathway is difficult to interpret.
Common reasons to order the test include:
- A gluten-free diet started before evaluation. Celiac antibodies can fall and the intestinal lining can heal after gluten is removed. HLA status remains unchanged, so a negative result may avoid an unnecessary gluten challenge.
- Blood tests and biopsy do not agree. Examples include positive tissue transglutaminase antibodies with a normal biopsy, mild intestinal changes with negative antibodies, or a biopsy taken after gluten restriction.
- A diagnosis was made years ago without adequate records. Genetic testing may help determine whether celiac disease remains biologically plausible before reconsidering lifelong dietary treatment.
- A first-degree relative has celiac disease. A negative result can greatly reduce the need for repeated celiac antibody screening. A positive result identifies a person who remains eligible for periodic screening.
- IgA deficiency or another condition complicates serology. IgG-based tests may still help, but HLA testing can add context.
- Dermatitis herpetiformis, type 1 diabetes, autoimmune thyroid disease, Down syndrome, Turner syndrome, or another associated condition raises suspicion. The result can refine—but not settle—the evaluation.
The test is less helpful when someone already has a clear diagnosis based on appropriate serology and intestinal biopsy while eating gluten. In that setting, a positive HLA result usually adds little, and a negative result should trigger review of the original diagnosis, the laboratory’s allele coverage, and possible rare exceptions.
Testing should answer a clinical question. Ordering it as a general wellness screen can create confusion because DQ2 and DQ8 are common. A healthy person with no symptoms or family history may receive a “positive” result that changes no care but causes avoidable anxiety or unnecessary dietary restriction.
Sample, preparation, and test methods
The laboratory can perform HLA-DQ testing on a blood sample, saliva sample, or cheek swab. Blood is common in hospital laboratories; saliva and cheek swabs are convenient for home collection or family studies. The sample contains white blood cells or shed cells with DNA.
No fasting is needed. A person does not need to eat gluten before the genetic test, and stopping gluten does not make the test falsely negative. Most medicines, supplements, infections, pregnancy, and time of day do not alter inherited HLA alleles.
For a cheek swab or saliva kit, follow collection instructions closely. Avoid food, drink, smoking, chewing gum, and tooth brushing for the stated period, often 30 minutes. Rub the swab firmly against the inner cheek or provide the required saliva volume. Poor cell yield can lead to a failed or delayed test, but it does not change the actual genotype.
Laboratories commonly use polymerase chain reaction with sequence-specific probes, sequence-specific primers, or next-generation sequencing. The method affects the level of detail. A low-resolution assay may simply identify DQ2 and DQ8 susceptibility. A high-resolution assay can identify alleles such as DQA105:01 and DQB102:01 and may determine gene dose.
Before testing, confirm what the panel detects. Useful questions include:
- Does it test both HLA-DQA1 and HLA-DQB1?
- Does it identify DQ2.5, DQ8, DQ2.2, and DQ7.5 or only broad DQ2/DQ8 categories?
- Does it report one versus two copies of DQB1*02?
- Does the laboratory provide a clinical interpretation rather than only raw allele names?
- Is the assay validated for the submitted sample type?
A technically accurate allele list can still be hard to interpret. When possible, use a clinical laboratory experienced in celiac HLA testing rather than relying on a recreational DNA report. Consumer genotyping may test only selected markers, infer HLA types indirectly, or omit rare alleles.
How to understand positive and negative results
A result should be read in two stages: first, determine whether a celiac-compatible HLA molecule can be formed; second, place that susceptibility beside the person’s symptoms and other tests.
Negative result
A negative result means the tested celiac-associated DQA1/DQB1 combinations were not found. This has high value because celiac disease is extremely uncommon without a compatible HLA background. In a person with uncertain symptoms, a well-performed negative test often shifts attention toward other causes such as irritable bowel syndrome, inflammatory bowel disease, lactose intolerance, wheat allergy, microscopic colitis, pancreatic disease, or non-celiac wheat sensitivity.
A negative report is strongest when the laboratory assessed the full relevant allele set. A report that tested only one marker or used limited imputation deserves more caution. If biopsy and antibody findings strongly support celiac disease despite a negative genetic result, the clinician may ask the laboratory to verify the sample, resolution, and allele interpretation.
Positive DQ2.5 result
DQ2.5 is the most important celiac susceptibility pattern. It may be encoded in cis, with the needed DQA1 and DQB1 alleles inherited together on one chromosome, or in trans, with complementary alleles inherited from opposite parents. Either arrangement can form the DQ2.5 molecule.
A positive DQ2.5 result does not diagnose disease. DQ2.5 is found in a substantial portion of the general population, while only a small percentage of genetically susceptible people develop celiac disease. The result supports continued evaluation when symptoms, family history, antibodies, or biopsy findings raise concern.
Positive DQ8 result
DQ8 also permits celiac disease but is less common among affected people than DQ2.5. It is encoded mainly by DQA103 and DQB103:02. DQ8 is also associated with type 1 diabetes, which helps explain why celiac screening is common in people with that condition. The result is not a diagnosis of either disease.
Gene dose and higher-risk combinations
Two copies of DQB102 can create more DQ2 molecules on antigen-presenting cells and are associated with higher celiac risk than a single copy. Reports may describe DQ2.5 homozygosity, DQ2.5 plus DQ2.2, or a “double-dose” DQB102 genotype. This can affect how strongly a specialist recommends ongoing screening in an at-risk child or family member, but it still cannot predict exactly whether or when disease will appear.
Partial DQ2 patterns carry lower or uncertain risk compared with complete DQ2.5. Do not interpret one allele in isolation. The HLA-DQB1 result and the DQA1 partner must be considered together.
How genetics fits with antibodies and biopsy
Celiac diagnosis usually combines several forms of evidence. Genetics describes lifelong susceptibility. Serology measures an immune response that is usually detectable while a person eats gluten. Biopsy evaluates tissue injury in the small intestine. Symptoms and response to diet add clinical context but are not specific enough by themselves.
| Test | What it shows | Main limitation |
|---|---|---|
| HLA-DQ2/DQ8 genotype | Whether celiac disease is genetically plausible | Positive results are common and do not show active disease |
| tTG-IgA with total IgA | Current celiac-associated antibody response | May become negative on a gluten-free diet or with IgA deficiency |
| EMA-IgA | Highly specific confirmatory antibody pattern | Operator-dependent and affected by gluten restriction |
| DGP-IgG or tTG-IgG | Useful in selected patients, including some with IgA deficiency | Performance varies by age and clinical setting |
| Duodenal biopsy | Villous injury, crypt changes, and increased lymphocytes | Changes can be patchy, nonspecific, or reduced after gluten avoidance |
A common sequence for someone currently eating gluten is tTG-IgA plus total IgA, followed by gastroenterology assessment and biopsy when indicated. Children may qualify for a specialist-led no-biopsy pathway under specific criteria, depending on the guideline and health system. HLA testing is not required in every routine case.
For someone already gluten-free, a negative HLA result can nearly close the celiac question. A positive result leaves the question open. The next step may be review of old records, a supervised gluten challenge, repeat serology, or endoscopy. A gluten challenge can provoke symptoms and should be planned with a clinician, especially in children, during pregnancy, with severe prior reactions, or when nutritional status is poor.
Symptom improvement without gluten is not proof of celiac disease. Wheat contains fermentable carbohydrates, and changing the diet may alter fiber, processed-food intake, or other ingredients. Starting a strict lifelong gluten-free diet solely because HLA-DQ2 or DQ8 is present can lead to nutritional gaps, expense, social burden, and difficulty obtaining a later definitive diagnosis.
Family testing and testing in children
First-degree relatives—parents, siblings, and children—have a higher celiac risk than the general population. HLA testing can divide relatives into two broad groups: those who lack celiac-compatible HLA and usually do not need repeated serologic screening, and those who carry susceptibility and should remain alert to symptoms or follow a clinician’s screening plan.
A positive child does not need a gluten-free diet unless celiac disease is diagnosed. Instead, the pediatrician may arrange periodic tTG-IgA and total IgA testing while the child eats gluten. The interval depends on family history, genotype, age, symptoms, and local guidance. Testing should occur sooner if growth slows, iron deficiency develops, bowel habits change, abdominal pain persists, puberty is delayed, or unexplained fatigue appears.
Children with type 1 diabetes, autoimmune thyroid disease, Down syndrome, Turner syndrome, Williams syndrome, selective IgA deficiency, or a close relative with celiac disease may undergo targeted screening even without classic diarrhea. Celiac disease can present with constipation, poor growth, dental enamel defects, low bone density, anemia, headaches, or no obvious symptoms.
Inheritance can look confusing because DQ2.5 may be assembled from alleles inherited together or from opposite parents. A parent who is not labeled “DQ2.5 positive” on a simplified report may still contribute one needed allele. Family testing should therefore compare actual DQA1 and DQB1 alleles when inheritance questions matter.
Prenatal or embryo testing for celiac-associated HLA is generally not clinically useful. The alleles are common, penetrance is low, and disease can be monitored and treated. HLA susceptibility does not predict severity, age of onset, or whether a child will ever need a gluten-free diet.
Limitations and common interpretation errors
The largest limitation is low positive predictive value. DQ2 and DQ8 are much more common than celiac disease, so most positive people do not have the condition. The test works better as an exclusion tool than as a stand-alone confirmation tool.
Several errors repeatedly cause confusion:
- Calling a positive genotype a diagnosis. Active celiac disease requires clinical and laboratory evidence beyond susceptibility.
- Assuming a negative DQ2/DQ8 label excludes every rare compatible genotype. Review whether the laboratory tested DQ2.2, DQ7.5, and complete DQA1/DQB1 combinations.
- Using the result to diagnose non-celiac gluten sensitivity. There is no validated HLA genotype that confirms that condition.
- Confusing celiac disease with wheat allergy. Wheat allergy involves different immune pathways and is assessed with allergy history, skin testing, specific IgE, and sometimes supervised challenge.
- Stopping gluten before standard testing without a plan. This may make serology and biopsy harder to interpret even though the genetic test remains valid.
- Treating a relative’s result as one’s own. Each person inherits a different combination and should be tested directly when the result will affect care.
- Overreading risk percentages. Published estimates vary by population, family history, age, and how disease was defined.
HLA typing also has technical limits. Low-resolution assays may collapse several alleles into a broad category. Direct-to-consumer data may use tag variants rather than sequencing the HLA genes. Rare recombination, allele dropout, sample mix-ups, and reporting differences can occur. A clinical laboratory can repeat or clarify unexpected findings.
Celiac disease itself has no single symptom pattern. A positive genotype may distract from another diagnosis, while a negative genotype may be falsely reassuring if the test was incomplete. The result should remain one part of a structured medical evaluation.
Next steps after the result
After receiving the report, obtain the exact allele list and the laboratory’s interpretation. Record whether the result identifies DQ2.5, DQ8, DQ2.2, DQ7.5, a DQB1*02 gene dose, or only a general positive/negative category.
For a negative result, ask whether the assay covered the full celiac-associated DQA1/DQB1 set. When it did, celiac disease usually falls far down the list of explanations. A clinician can investigate other digestive, inflammatory, allergic, endocrine, or nutritional causes based on the symptoms.
For a positive result in a person eating gluten, the usual next tests are celiac serology and total IgA. Do not begin a gluten-free diet before completing the diagnostic plan unless a clinician advises it. For a positive result in someone already gluten-free, discuss whether old records are enough, whether a supervised gluten challenge is appropriate, and what amount and duration would be safe.
Seek prompt medical care for major weight loss, dehydration, persistent vomiting, black or bloody stool, severe abdominal pain, fainting, marked weakness, or signs of significant anemia. In children, urgent assessment is appropriate for poor intake, lethargy, dehydration, or rapid loss of weight.
A genetics professional can help when the allele pattern is unusual, several relatives are affected, or a report from a consumer service conflicts with clinical testing. For most people, a gastroenterologist, primary care clinician, pediatrician, and dietitian experienced in celiac disease can translate the result into a practical plan.
A practical way to use the report is to separate exclusion from confirmation. A complete negative result can make further gluten challenge unnecessary when the original diagnosis is doubtful. A positive result cannot confirm celiac disease, so the person should not interpret symptom improvement on a gluten-free diet as proof.
When a gluten challenge is being considered, the amount and duration depend on age, previous reaction, current diet, and the planned endpoint. The clinician may aim for repeat serology, biopsy, or both. A short challenge can be falsely reassuring, while an unnecessarily aggressive challenge can cause substantial illness. It should be supervised rather than improvised from internet instructions.
The report should be kept with medical records because the genotype never changes. Repeating the same test after years on a gluten-free diet adds no information. Future relatives should have their own testing when it would change screening, because siblings can inherit different DQA1 and DQB1 combinations.
References
- Celiac Disease 2025 (Review)
- European Society for the Study of Coeliac Disease 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 1: Diagnostic Approach 2025 (Guideline)
- Clinical settings in which human leukocyte antigen typing is still useful in the diagnosis of celiac disease 2025 (Review)
- Insights into the diagnosis of celiac disease: a critical appraisal 2024 (Review)
- Laboratory Testing for HLA Genotypes Associated with Coeliac Disease 2023 (Guideline)
- Current guidelines for the management of celiac disease: A systematic review with comparative analysis 2022 (Systematic Review)
Disclaimer
This information explains HLA-DQ2 and HLA-DQ8 testing and is not a diagnosis or a substitute for care from a qualified clinician. Do not start or stop a gluten-free diet, arrange a gluten challenge, or change a child’s diet based only on a genetic result. A clinician should interpret the report with symptoms, celiac serology, total IgA, nutritional findings, and biopsy results when needed.
